toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/acutrialsocom/public_html/refbase-ocom/includes/include.inc.php on line 5275
  Record Links
Author (up) Shen, Y.; Liu, L.; Chiang, J.S.; Meng, Z.; Garcia, M.K.; Chen, Z.; Peng, H.; Bei, W.; Zhao, Q.; Spelman, A.R.; Cohen, L. openurl 
  Title Randomized, placebo-controlled trial of K1 acupoint acustimulation to prevent cisplatin-induced or oxaliplatin-induced nausea Type of Study Journal Article
  Year 2015 Publication Cancer Abbreviated Journal  
  Volume 121 Issue 1 Pages 84-92  
  Keywords AcuTrials; Neoplasms; Chemotherapy Side Effects; Nausea; Cancer; Antineoplastic Agents; Liver Cancer; Acu + Usual Care Versus Sham + Usual Care; Transcutaneous Electrical Nerve Stimulation; Tens; TCM Acupuncture Style; Fixed Acupuncture Protocol; Sham Control; Non Penetrating Sham, Electrical; Sham Acupoint Control; Rct  
  Abstract BACKGROUND: Greater than 70% of patients with cancer experience chemotherapy-induced nausea and vomiting. In the current study, the authors examined the effects of electrostimulation of the K1 acupoint located on the sole of the foot because it is believed to have the potential to control chemotherapy-induced nausea and vomiting. METHODS: In this trial, 103 patients diagnosed with primary or metastatic liver cancer were recruited before transcatheter arterial infusion (TAI) of cisplatin or oxaliplatin and randomized to either group A (51 patients who were treated with the antiemetic tropisetron and acustimulation at the K1 acupoint for 20 minutes approximately 1 to 2 hours before TAI on the first day and then daily for the subsequent 5 days) or group B (52 patients who were treated with tropisetron and electrostimulation at a placebo point on the heel). The rate, intensity, and duration of nausea and vomiting were collected at baseline and then daily for 5 days after TAI. Quality of life was assessed daily using the MD Anderson Symptom Inventory and the EuroQoL scale. RESULTS: No differences were found between groups A and B with regard to the incidence and degree of nausea or vomiting on day 1 or the following 5 days. Patients in group A had better EuroQoL scores compared with patients in group B (72.83 in group A vs 65.94 in group B; P =.04) on day 4 but not on the other days. No group differences were noted at any time point for MD Anderson Symptom Inventory scores. CONCLUSIONS: Electrostimulation of K1 combined with antiemetics did not result in initial prevention of cisplatin-induced or oxaliplatin-induced nausea or vomiting.  
  Address Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.  
  Publisher (c) 2014 American Cancer Society.
  Language Number of Treatments 6  
  Treatment Follow-up 5 Days Frequency >1/WK Number of Participants 103  
  Time in Treatment 1 Week Condition Chemotherapy side-effects
  Disease Category Neoplasms OCSI Score  
  Notes Date of Input: 4/7/2015; Date Modified: 5/7/2015; Availability: --In File--; Priority: Normal; Chemotherapy Side Effects; Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; eng; Web: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=25204437 Approved no  
  Call Number OCOM @ refbase @ Serial 1690  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: